High Bleeding Risk Patients With DES: Insights from SENIOR and LEADER-FREE Trials

MC Morice MD, FESC, FACC Massy France

TCTAP 2018 Seoul



Disclosure Statement of Financial Interest

I, Marie Claude Morice am shareholder and CEO of CERC, the CRO conducting the Leaders free and Master DAPT trials




The High bleeding risk patient

• Who are they?




High Bleeding Risk Patients (HBR)




DAPT « all comers » trials <u>ex</u>clusion criteria (**X**) vs. LEADERS FREE <u>in</u>clusion criteria (**X**)

	EXCELLENT	RESET	ARCTIC	OPTIMIZE	DAPT DES	LEADERS FREE
Low Hb or thrombocytopenia	×	×	×			1
Recent bleeding	×	×	×			1
Anticoagulants	×		×		×	1
Need for surgery	×		×	×	×	1
Renal or hepatic failure	×	×	×			1
STEMI and/or GP 2b3a blockers	×		×	×		not excluded
Anticipated difficulties with long term DAPT	×	×	×		×	1

BioFreedom™ Drug Coated Stent (DCS)





Advantages:

- Avoid any possible polymer-related adverse effects
- Rapid drug transfer to vessel wall (98% within one month²)
- Good fit with short DAPT

LEADERS FREE Trial Design


Prospective, double-blind randomized (1:1) trial 2466 High bleeding risk (HBR) PCI patients



DAPT mandated for 1 month only, followed by long-term SAPT


- Primary safety endpoint: Composite of cardiac death, MI, definite / probable stent thrombosis at 1 year (non-inferiority then superiority)
- **Primary efficacy endpoint:** Clinically-driven TLR at 1 year (superiority)

Leaders Free Inclusion Criteria Applied (1.7 criteria / patient)




Urban P et al, NEJM 2015; 373: 2038-47

Leaders free Efficacy and Safety Endpoints @ 1 Years



LF Elderly population: Bleeding events



None of bleeding category differs at p < 0.05





A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS with Short DAPT in Patients with Coronary Artery Disease Older than 75 Years. The SENIOR Trial

O. Varenne, S. Cook, G. Sideris, S. Kedev, T. Cuisset, D. Carrié, T. Hovasse, P. Garot, R. El Mahmoud, C. Spaulding, G. Helft, J. Diaz Fernandez, S. Brugaletta, E. Pinar Bermudez, J. Mauri Ferre, P. Commeau, E. Teiger,

K. Bogearts, M. Sabate, M-C. Morice and P. Sinnaeve,

for the SENIOR investigators.

SENIOR Trial design


Randomized (1:1), single blind trial 1,200 patients aged 75 years and above

Tailored DAPT: 1 mo in stable and 6 mo in ACS pts Prespecified by the investigator prior to randomization



Primary End Point 1y: all-cause mortality, non-fatal MI, stroke, IDTLR ondary End Points 1y: Bleeding BARC 2-5/3-5, stent thrombosis


Synergy[™] DES used in SENIOR



TCTAP 2018


Neredith I. et al. EuroInterv 2017 (in Press) doi:10.4244/EU-D-17-00529

Primary End Point






MACCE Components



TAP2018



Safety Endpoints




The High bleeding risk patient

• Some criteria of HBR are also predicting thrombotic events.....




First coronary thrombotic or major bleeding events according to LEADERS FREE inclusion criteria*





Leaders Free: 1-year Mortality Following Major Bleed (BARC 3-5) or Coronary Thrombotic Event (MI and/or ST)



Mortality was 6% after 1 year for patients without thrombotic or major bleeding events

The High bleeding risk patient

• Does the scores helps?



2017 ESC Focused Update on DAPT in Coronary Artery Disease

(European Heart Journal 2017 - doi:10.1093/eurheartj/ehx419)

	PRECISE-DAPT score"	DAPT score ¹⁵		
Time of use	At the time of coronary stenting	After 12 months of uneventful DAPT		
DAPT duration strategies assessed	Short DAPT (3–6 months) vs. Standard/iong DAPT (12–24 months)	Standard DAPT (vs. Long DAPT (30		
Score calculation*	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Age 275 65 to <75 <65 Cigarette smoking Diabetes mellitus MI at presentation Prior PCI or prior MI Paclitaxel-eluting stent Stent diameter <3 mm CHF or LVEF <30% Vein graft stent	-2 pt -1 pt 0 pt +1 pt +1 pt +1 pt +1 pt +1 pt +1 pt +1 pt +2 pt +2 pt	
Score range	0 to 100 points	-2 to 10 pc	pints	
Decision making cut-off suggested	Score ≥25 → Short DAPT Score <25 → Standard/Iong DAPT	Score ≥2 → Long DAPT Score <2 → Standard DAPT		
Calculator	www.precisedaptscore.com	www.daptstudy.org		

1018

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

Risk Scores From PARIS

J Am Coll Cardiol 2016;67:2224-34

Usman Baber, MD, MS," Roxana Mehran, MD," Gennaro Giustino, MD," David J. Cohen, MD, MSc,"

Parameter	Score
Age, yrs	
<50	0
50-59	+1
60-69	+2
70-79	+3
≥80	+4
BMI, kg/m ²	
<25	+2
25-34.9	0
≥35	+2
Current smoking	
Yes	+2
No	0
Anemia	
Present	+3
Absent	0
CrCl <60 ml/min	
Present	+2
Absent	0
Triple therapy on discharge	
Yes	+2
No	0

Parameter	Score
Diabetes mellitus	
None	0
Non-insulin-dependent	+1
Insulin-dependent	+3
Acute coronary syndrome	
No	0
Yes, Tn-negative	+1
Yes, Tn-positive	+2
Current smoking	
Yes	+1
No	0
CrCl <60 ml/min	
Present	+2
Absent	0
Prior PCI	
Yes	+2
No	0
Prior CABG	
Yes	+2
No	0

Major bleeding during first year



CTAP2018

The HBR patients, unanswered questions

* Which age limit to qualify for HBR?

* For patients on oral anticoagulant, - how long should DAPT be?

* renal failure alone?

* Cancer (about 10% in LF) which disease to treat first?

* Should we use risk scores? If yes which one? (no dedicated HBR score, for example, DAPT score can be applied after one year of DAPT only....)

*Wich DAPT optimal duration for HBR?

<u>MA</u>nagement of high bleeding risk patients post bioresorbable polymer coated <u>STE</u>nt implantation with an abb<u>R</u>eviated versus prolonged <u>DAPT</u> regimen – MASTER DAPT

Ultimaster, 4300pts, 110 sites, 60 countries, near 1000 pts randomised





The ARC HBR initiative

Leads Philip Urban, Marie Claude Morice, Roxana Mehran, Mitch Krucoff

List of experts:

Robert Byrne, Roisin Colleran, Davide Capodanno, Thomas Cuisset, Pedro Eedermans, John Gregson, Michael Haude, Stephan James, Marco Valgimigli, Dominic Angiolillo, Don Cuplic, John Eikelboom, Matthew Price, Sunil Rao, Roseann White, Hyo soo Kim, Takeshi Kimura, Michael Gibson, Norman Stockbridge, John Lashinger, Darren Mylotte, Olivier Varenne, Andrew Farb, Gerrit Anne Van Es, Robert Yeh.

First meeting in Washington done in April



IN SUMMARY remaining gaps:

Identification of HBR patients

Scores vs clinical judgment, <u>dedicated score needed</u> Age and OAC are main factors, but many others exists, (major / minor criteria) role of the ARC HBR task force

PCI strategies specific to HBR patients

Dedicated devices?, no room for BMS, are all last generation DES disconnected from DAPT duration? Optimal PCI technic

Antithrombotic strategies tailored for HBR patients

Awaiting DAPT duration trials results (Master DAPT)